Intelligence Feed event · Equity · 2026-10-14

    UnitedHealth Posts 60% YoY EPS Surge as J&J Earnings Decline 7.5% in Q3

    Question

    UnitedHealth Posts 60% YoY EPS Surge as J&J Earnings Decline 7.5% in Q3

    Direct answer

    UnitedHealth and Johnson & Johnson reported contrasting Q3 performance. UnitedHealth achieved a 60% YoY increase in EPS following medical cost management gains. Johnson & Johnson saw pharmaceutical segment gains offset by other divisions, resulting in a 7.5% EPS contraction, while both companies increased full-year projections.

    Original publisher
    Market Ontology
    Evidence through
    2026-10-14
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “UnitedHealth Posts 60% YoY EPS Surge as J&J Earnings Decline 7.5% in Q3”, revision 1, evidence through 2026-10-14. https://marketontology.com/market-events/2026-10-14/unitedhealth-posts-60-yoy-eps-surge-as-j-j-earnings-decline-7-5-in-q3-cea9e7

    EQUITY
    UnitedHealth Posts 60% YoY EPS Surge as J&J Earnings Decline 7.5% in Q3
    UnitedHealth and Johnson & Johnson reported contrasting Q3 performance. UnitedHealth achieved a 60% YoY increase in EPS following medical cost management gains. Johnson & Johnson saw pharmaceutical segment gains offset by other divisions, resulting in a 7.5% EPS contraction, while both companies increased full-year projections.
    UNHJNJ
    Impact
    80
    OCT 14
    SIG
    88%
    UNHJNJ
    UnitedHealth Posts 60% YoY EPS Surge as J&J Earnings Decline 7.5% in Q3
    UnitedHealth and Johnson & Johnson reported contrasting Q3 performance. UnitedHealth achieved a 60% YoY increase in EPS following medical cost management gains. Johnson & Johnson saw pharmaceutical segment gains offset by other divisions, resulting in a 7.5% EPS contraction, while both companies increased full-year projections.
    → Medical loss ratio improvement expands UNH operating margins relative to diversified pharma peers.
    Impact
    UnitedHealth and Johnson & Johnson reported contrasting Q3 performance. UnitedHealth achieved a 60% YoY increase in EPS following medical cost management gains. Johnson & Johnson saw pharmaceutical segment gains offset by other divisions, resulting in a 7.5% EPS contraction, while both companies increased full-year projections.
    Affected
    UNHJNJ
    Transmission
    Medical loss ratio improvement expands UNH operating margins relative to diversified pharma peers.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    UNHoperating margin expansion via reduced medical loss ratioUp1-5dUnitedHealth beat expectations with 60% YoY EPS growth driven by improved medical cost management.
    JNJguidance upward revision offsetting Q3 headline EPS contractionMixed1-5dJ&J saw earnings decline 7.5% YoY despite pharmaceutical growth but raised full-year guidance.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    JNJMixed253.91 2026-10-14-0.25%PendingPending
    UNHUpagreed395.62 2026-10-14+2.79%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month